- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01720134
The Impact of Legally Enforced Embryo Transfer Policy (Belgian Law 2003) on Cumulative Delivery Rate.
March 29, 2017 updated by: Sophie Debrock, KU Leuven
Multiple pregnancy (MP) is associated with significant fetomaternal complications and a high cost.
The multiple pregnancy rate per cycle (MPR) of treatment with Assisted Reproductive Technology (ART) is 25 % or higher even in countries where ART is reimbursed, much higher than the 1% after natural conception, related to the number of embryos transferred, and preventable by single embryo transfer (SET).
In Belgium, the laboratory costs for 6 fresh ART cycles are reimbursed for female patients younger than 43 with a Belgian insurance number since July 2003, but only if a limited number of embryos is transferred depending on female age and cycle rank.
Although this policy has resulted in a significant reduction in the MPR after ART in Belgium from 24 % to 13 %, available data are cycle based and it is unknown if the cumulative delivery rate per patient is affected by this legislation.
The aim of this study was to test the hypothesis that Belgian ART legislation since 2003, coupling lab reimbursement to restriced embryo transfer policy, has resulted in a reduced CDR when compared to the situation before 2003.
Study Overview
Status
Completed
Study Type
Observational
Enrollment (Actual)
1258
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Leuven, Belgium, 3000
- Leuven University Fertility Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 43 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
patients undergoing IVF/ICSI cycles
Description
Inclusion Criteria:
- patients with their first IVF/ICSI cycle
Exclusion Criteria:
- cycles without oocytes or sperm, oocyte reception cycles, embryo reception cycles, cycles with preimplantation genetic diagnosis/screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
after legislation 1st july 2003
2003-2006
|
before legislation 1st july 2003
1999-2003
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
cumulative delivery rate
Time Frame: 1999-2006
|
1999-2006
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2010
Primary Completion (Actual)
June 1, 2012
Study Completion (Actual)
July 1, 2012
Study Registration Dates
First Submitted
October 25, 2012
First Submitted That Met QC Criteria
October 31, 2012
First Posted (Estimate)
November 2, 2012
Study Record Updates
Last Update Posted (Actual)
March 30, 2017
Last Update Submitted That Met QC Criteria
March 29, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- S53562
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Impact of Legislation on Cumulative Delivery Rate
-
Ospedale Regionale Bellinzona e ValliCompletedImpact of Anesthetic Choice on Costs
-
University of California, San FranciscoFood and Drug Administration (FDA)RecruitingThe Impact of Excipients on Drug AbsorptionUnited States
-
RWTH Aachen UniversityUnknownThe Impact of Oxytocin on Social CognitionGermany
-
University of PennsylvaniaMerakey Behavioral HealthCompletedImpact of Feedback on Symptoms and Trust/Respect on OutcomesUnited States
-
University of OklahomaRecruitingImpact of Supervision on Endoscopy Simulation CurriculumUnited States
-
Agency for Healthcare Research and Quality (AHRQ)CompletedImpact of Electronic Prescribing on Medication SafetyUnited States
-
St. Boniface HospitalManitoba Starch Products; National Microbiology Laboratory, CanadaCompletedFocus of Study; Impact of MSPrebiotic on Gastrointestinal MicrobiotaCanada
-
Chang Gung UniversityChang Gung Memorial HospitalCompleted
-
Brigham and Women's HospitalAgency for Healthcare Research and Quality (AHRQ)CompletedImpact of Barcode Technology on Medication ErrorsUnited States
-
Quadram Institute BioscienceNorfolk and Norwich University Hospitals NHS Foundation TrustCompleted